Greccas (Ticagrelor)

Greccas is indicated for the management of several acute and chronic cardiovascular conditions where inhibition of platelet aggregation is required.

• Acute coronary syndrome (ACS) including unstable angina and myocardial infarction.
• Post‑myocardial infarction secondary prevention.
• Patients with a history of myocardial infarction to reduce risk of recurrent thrombotic events.
• Use in combination with low‑dose aspirin as part of dual antiplatelet therapy.

The safety profile of ticagrelor, the active component of Greccas, includes a range of observed adverse reactions.

Common

• Dyspnea.
• Headache.
• Nausea.
• Diarrhea.
• Minor bleeding such as gum or nosebleeds.

Serious

• Severe bleeding (intracranial or gastrointestinal).
• Thrombotic thrombocytopenic purpura (rare).
• Elevated hepatic enzymes.
• Bradyarrhythmias.
• Hypersensitivity reactions including rash or angioedema.

When prescribing Greccas, clinicians should evaluate patient-specific factors and monitor for potential complications.

• Assess bleeding risk before initiating therapy.
• Use caution in patients with a history of intracranial hemorrhage.
• Adjust therapy in severe hepatic impairment.
• Avoid in patients with active pathological bleeding.
• Monitor for dyspnea and discontinue if severe.
• Consider renal function; dose adjustment may be required in severe renal impairment.

Greccas can interact with several medications that affect hemostasis or drug metabolism.

Avoid

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin).
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) when combined with aspirin.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants) without careful monitoring.

Use with caution

• Moderate CYP3A4 inhibitors (e.g., diltiazem).
• CYP3A4 inducers (e.g., rifampin) may reduce efficacy.
• Other antiplatelet agents (e.g., clopidogrel) may increase bleeding risk.